Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2026 07:00 ET | Source: Annovis Bio Inc.

Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease

Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions...
July 02, 2026 03:30 ET | Source: Xeltis

Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis

Xeltis announces that it has exceeded 50% enrollment in its US pivotal trial for aXess™
June 25, 2026 08:15 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX,” or the “Company”) (Nasdaq:BRTX), a late-stage clinical regenerative medicine company...
June 18, 2026 08:15 ET | Source: BioRestorative Therapies, Inc

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

Accomplished commercial aesthetics veteran to drive sales channel expansion and pipeline development MELVILLE, N.Y., June 18, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
June 10, 2026 09:15 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected...
May 26, 2026 11:00 ET | Source: BioRestorative Therapies, Inc

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues Phase 3 readiness activities following FDA Type B...
May 21, 2026 11:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
April 16, 2026 16:26 ET | Source: Carnegie

Carnegie research: Students more concerned with higher ed’s feasibility

Westford, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Carnegie, the student connection company, today released The Next Gen Learners Report: Cost of Living, Vibes, and Radical Transparency. Based on a...
March 18, 2026 08:07 ET | Source: Vanderbilt Report and Artelo Biosciences

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Artelo Biosciences (NASDAQ: ARTL) enters ophthalmology space with a fully funded evaluating ART27.13 in glaucoma patients.
February 12, 2026 04:00 ET | Source: Adlai Nortye Ltd.

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...